All studies but one required documented FGFR abnormalities for eligibility. Adverse events (AEs) were graded from 1 to 5 (G1-5) on the basis of the Common Terminology Criteria for Adverse Events v5.0.

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

The thymus is a crucial training ground for T-cells, the body's "white knights," where they learn to battle the various diseases they may encounter. Thymic function shrinks to nearly nothing as we age ...

Incyte today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 ?

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

A study demonstrates the role of the Galectin-1 protein in the nucleus of the cells surrounding the tumor -- fibroblasts -- contributing to their activation. Activated fibroblasts promote tumor growth ...

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates-only 10% after five years.

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...